Frontiers in Immunology (Apr 2024)

Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation

  • Ying Jiang,
  • Dan Feng,
  • Jun Zhu,
  • Daolin Wei,
  • Chuxian Zhao,
  • Huixia Liu,
  • Shan Shao,
  • Chun Wang

DOI
https://doi.org/10.3389/fimmu.2024.1381308
Journal volume & issue
Vol. 15

Abstract

Read online

Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials. However, most of them were bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT). We described successful treatment with preventive donor-derived anti-CD7 CAR-T therapy in a case of refractory T lymphoblastic lymphoma following allo-HSCT, who could not receive autologous anti-CD7 CAR-T products due to the low-quality of T lymphocytes. To date, the patient’s complete remission has persisted for 20 months after HSCT.

Keywords